Drug Type Small molecule drug |
Synonyms CAL-120, GS-9820 |
Target |
Mechanism PI3Kβ inhibitors(Phosphatidylinositol 3 kinase beta inhibitors), PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H16FN7O |
InChIKeyDOCINCLJNAXZQF-LBPRGKRZSA-N |
CAS Registry870281-34-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lymphoma | Phase 2 | NL | 29 May 2013 | |
Chronic Lymphocytic Leukemia | Phase 2 | NL | 28 Apr 2013 | |
Solid tumor | Preclinical | US | - |
Phase 1 | 39 | GS-9820 50mg | mdmouohyrg(yaehwhmozc) = 2, 5.1% gifzflgmdy (ibcdplrtex ) View more | Positive | 09 Jun 2015 | ||
GS-9820 100mg | |||||||
Phase 1 | 39 | xpjsmmxrta(tqwrcxvwjl) = 8 subjects reported pneumonia mdwkegkafx (ceyxltvkmj ) View more | - | 21 May 2015 | |||